AbbVie Inc., through its subsidiary Allergan Aesthetics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval application for SKINVIVE by JUVÉDERM®. This application seeks to expand the indication of SKINVIVE to include the reduction of neck lines, aiming to improve neck appearance. Already approved in the U.S. for enhancing cheek skin smoothness in adults over 21, SKINVIVE by JUVÉDERM® could become the first hyaluronic acid injectable treatment option targeting neck lines if approved. The application is supported by a clinical study that met all primary and secondary endpoints.